AHL Investment Management Inc. Buys 550 Shares of Pfizer Inc. (NYSE:PFE)

AHL Investment Management Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,437 shares of the biopharmaceutical company’s stock after buying an additional 550 shares during the quarter. Pfizer accounts for approximately 1.6% of AHL Investment Management Inc.’s holdings, making the stock its 22nd biggest holding. AHL Investment Management Inc.’s holdings in Pfizer were worth $2,267,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its holdings in shares of Pfizer by 2.8% during the second quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company’s stock valued at $20,684,000 after acquiring an additional 20,140 shares in the last quarter. Sompo Asset Management Co. Ltd. boosted its position in Pfizer by 15.1% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 22,470 shares of the biopharmaceutical company’s stock valued at $629,000 after acquiring an additional 2,950 shares in the last quarter. Schwerin Boyle Capital Management Inc. boosted its holdings in shares of Pfizer by 8.2% during the 2nd quarter. Schwerin Boyle Capital Management Inc. now owns 775,125 shares of the biopharmaceutical company’s stock valued at $21,688,000 after buying an additional 58,850 shares in the last quarter. Kowal Investment Group LLC increased its stake in shares of Pfizer by 10.3% in the 2nd quarter. Kowal Investment Group LLC now owns 18,834 shares of the biopharmaceutical company’s stock worth $527,000 after acquiring an additional 1,757 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in Pfizer by 7.3% during the second quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock worth $23,661,000 after acquiring an additional 57,825 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $26.30 on Monday. The company has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The business’s 50-day moving average is $26.08 and its 200 day moving average is $27.99. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the company posted ($0.17) EPS. The business’s revenue was up 31.2% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Analysts Set New Price Targets

Several research firms have commented on PFE. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Guggenheim cut their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.